Abstract
The aim of this study was to improve the solubility of etoposide–ethylcellulose (ET–ETO) microparticles using the freeze-drying technique. Ethylcellulose (EC) microparticles loaded with etoposide (ETO) were prepared with different drug–polymer molar ratios of 1:1, 1:3, 1:6, and 1:20 by the solvent evaporation method. The size of the prepared microparticles was 0.088 µm. The results showed that the amount of ETO encapsulated into the microparticles was 387.3, 365.0, 350.0, and 250 µg/50 mg microparticles for microparticles with drug–polymer ratios of 1:1, 1:3, 1:6, and 1:20, respectively. The FT-IR spectra showed no chemical interaction between ETO and the polymer in the solid state. The results obtained from the dissolution experiment showed that the freeze-dried microparticles were stable in 0.1 N HCl (gastric pH) for 2 h. At pH 7.4, the ETO release was 60 to 70% within the first 15 min and approximately 100% within 30 min. Results from the application of different dissolution models showed that the equations that best fit the dissolution data for the ET–ETO microparticles at pH 7.4 were the Higuchi and Peppas model equations. The in vitro cytotoxicity assay of free ETO and freeze-dried microspheres prepared in this study with a drug–polymer ratio of 1:1 was performed in two mammalian cancer cell lines, MCF-7 (for bone cancer of the mammary organ) and Caco-2 (for mammalian epithelial colorectal adenocarcinoma). The results showed that the half-maximal inhibitory concentrations (IC50 values) for ETO and freeze-dried ET–ETO microparticles were 18.6 µM and 27.1 µM, respectively. In conclusion, freeze-dried ET–ETO is a promising formulation for developing a fast-dissolving form of ETO with a significant antiproliferative activity against the tested cell lines used in this study. It is a promising formulation for local duodenal area targeting.
Highlights
Etoposide (ETO semisynthetic podophyllotoxin derivative, with a molecular formula of C29H32O13) has an anticancer activity used for treating various tumours, such as lymphoma, small cell lung cancer, and leukaemia
Etoposide is classified as class IV in the Biopharmaceutics Classification System (BCS) with insufficient aqueous solubility and permeability, making etoposide a poor candidate for oral administration, resulting in many formulations of etoposide being prepared as injections
Characterization of the Prepared Ethylcellulose Microparticles Loaded with ETO The size diameter of the prepared microparticles was measured using a laser particle size analyser (SLAD-400 from Shimadzu, Japan), and their morphology was investigated
Summary
Etoposide (ETO semisynthetic podophyllotoxin derivative, with a molecular formula of C29H32O13) has an anticancer activity used for treating various tumours, such as lymphoma, small cell lung cancer, and leukaemia. Several techniques have been reported in previous studies to enhance the solubility of poorly soluble drugs. Freeze-drying has been used to improve drug solubility in numerous solid oral dosage forms, such as solid dispersions of powders, tablets, capsules, and microparticles. The preparation of microparticles involves freeze-drying for pharmaceutical formulations that produce highly porous microparticles with a low density that are more fragile [1]. The freeze-drying technique is expected to reduce the number of particles and produce spherical particles with comparatively large geometric diameters and low particle mass densities [3]. Using a dual emulsion–solvent evaporation technique, Ungaro et al produced gas-powered, large, porous, polymer-centred (LPGA) polymers [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
